Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has received an average rating of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $24.71.
A number of analysts recently weighed in on the company. JMP Securities downgraded Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Wedbush restated an “outperform” rating and issued a $22.84 price target (down from $25.00) on shares of Syros Pharmaceuticals in a research note on Thursday, August 10th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Cann restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Finally, Oppenheimer Holdings, Inc. set a $28.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 12th.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2017/09/10/syros-pharmaceuticals-inc-syrs-receives-21-77-consensus-price-target-from-brokerages.html.
Shares of Syros Pharmaceuticals (SYRS) traded up 1.12% on Tuesday, hitting $17.18. The stock had a trading volume of 104,904 shares. The company has a market cap of $451.15 million, a price-to-earnings ratio of 3.12 and a beta of -3.34. The firm’s 50-day moving average is $20.64 and its 200-day moving average is $16.59. Syros Pharmaceuticals has a one year low of $10.22 and a one year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. On average, analysts expect that Syros Pharmaceuticals will post ($2.09) EPS for the current fiscal year.
In related news, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at $273,125. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Richard A. Young sold 3,282 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.09, for a total value of $72,499.38. Following the transaction, the director now directly owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,564 shares of company stock valued at $476,803.
Hedge funds have recently modified their holdings of the stock. Nationwide Fund Advisors raised its holdings in Syros Pharmaceuticals by 249.8% during the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after purchasing an additional 10,466 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Syros Pharmaceuticals during the first quarter worth $185,000. Rhumbline Advisers acquired a new position in Syros Pharmaceuticals during the second quarter worth $198,000. Finally, New York State Common Retirement Fund raised its holdings in Syros Pharmaceuticals by 167.9% during the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after purchasing an additional 8,399 shares during the last quarter. 59.61% of the stock is owned by hedge funds and other institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.